The U.S. Patent and Trademark Office's Patent Trial and Appeal Board issued what may be the first final written decision on an inter partes review in a pharma case.
June 26, 2014 at 03:16 PM
1 minute read
Companies that have been closely watching the use of inter partes review to challenge patents received an important signal on June 20 when the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) invalidated a score of pharmaceutical claims.
Joseph Cwik, a litigation partner at Husch Blackwell, said it is believed to be the first time the PTAB has issued a final written decision on an inter partes review (IPR) in a pharma case.
Presented by BigVoodoo
General Counsel Summit is the premier event for in-house counsel, hosting esteemed legal minds from all sectors of the economy.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Predictive reporting, trend analysis, peer guidance and a practical playbook to help genetal counsels succeed in their increasingly high stakes roles as risk managers and corporate strategists
